{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Alden SL"],"funding":["NIMHD NIH HHS","NCI NIH HHS"],"pagination":["1312-1317"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10356567"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(7)"],"pubmed_abstract":["Combination anti-PD-(L)1/CTLA-4 blockade is approved in patients with hepatocellular carcinoma (HCC) in the first-line setting or after sorafenib, but whether this treatment has efficacy after prior anti-PD-(L)1 therapy is unknown. We performed a multicenter retrospective review of patients with advanced HCC treated with ipilimumab plus nivolumab after prior anti-PD-(L)1 therapy, excluding patients with prior anti-CTLA-4 treatment. Of the 32 patients who met our inclusion criteria, prior anti-PD-(L)1 regimens included atezolizumab plus bevacizumab (50%, <i>n</i> = 16), other anti-VEGF plus anti-PD-(L)1 combinations (31%, <i>n</i> = 10), and anti-PD-(L)1 monotherapy (19%, <i>n</i> = 6). The median number of prior systemic therapies was 2 (range, 1-8). The objective response rate with ipilim"],"journal":["Cancer research communications"],"pubmed_title":["Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma."],"pmcid":["PMC10356567"],"funding_grant_id":["P30 CA006973","U01 CA212007","P50 CA062924","R01 CA256977","R01 MD012565","R01 CA265009"],"pubmed_authors":["Kao C","Alden SL","Griffith P","Ho WJ","Shu D","Singal AG","Hsiehchen D","Noonan A","Baretti M","Lim M","Yarchoan M","Kamel I"],"additional_accession":[]},"is_claimable":false,"name":"Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.","description":"Combination anti-PD-(L)1/CTLA-4 blockade is approved in patients with hepatocellular carcinoma (HCC) in the first-line setting or after sorafenib, but whether this treatment has efficacy after prior anti-PD-(L)1 therapy is unknown. We performed a multicenter retrospective review of patients with advanced HCC treated with ipilimumab plus nivolumab after prior anti-PD-(L)1 therapy, excluding patients with prior anti-CTLA-4 treatment. Of the 32 patients who met our inclusion criteria, prior anti-PD-(L)1 regimens included atezolizumab plus bevacizumab (50%, <i>n</i> = 16), other anti-VEGF plus anti-PD-(L)1 combinations (31%, <i>n</i> = 10), and anti-PD-(L)1 monotherapy (19%, <i>n</i> = 6). The median number of prior systemic therapies was 2 (range, 1-8). The objective response rate with ipilim","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2025-04-05T14:52:18.911Z","creation":"2025-04-05T14:52:18.911Z"},"accession":"S-EPMC10356567","cross_references":{"pubmed":["37484200"],"doi":["10.1158/2767-9764.CRC-23-0072"]}}